Drug Trial Radar · NCT04938752
Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects (DA-2811)
Last checked: Nov 19, 2026Latest source record: Jun 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jul 8, 2021
Primary completion
Aug 20, 2021
Study completion Aug 20, 2021
Sponsor
- Lead sponsor
- Dong-A ST Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is the phase I study to evaluate the pharmacokinetics and safety of DA-2811 and DA-2811-R after a single oral dose in healthy volunteers.
Conditions
- Healthy
Interventions
DA-2811Drug
single dose administration (one tablet once a day)
DA-2811-RDrug
single dose administration (one tablet once a day)
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUClastTime frame: pre-dose~48 hours post-dose
- CmaxTime frame: pre-dose~48 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Bundang Hospital
Gyeonggi-do, Seongnam-si, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.